- mail us help@24marketresearch.com
- Int'l 1(332) 2424 294 (Int'l)
TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
The Asia Pacific Cephalosporin Antibiotics API market size was valued at US$ 3.26 billion in 2024 and is projected to reach US$ 4.18 billion by 2030, at a CAGR of 4.2% during the forecast period 2024-2030.
Cephalosporin antibiotics APIs are active pharmaceutical ingredients used in the production of a broad class of antibiotics, effective against various bacterial infections and widely used in both human and veterinary medicine.
The Asia Pacific cephalosporin antibiotics API market is substantial, driven by the region's large pharmaceutical manufacturing base and high demand for antibiotics. China dominates with a 50% market share, followed by India at 30% and Japan at 10%. In 2023, third-generation cephalosporins accounted for 45% of total production, with second-generation at 30%. The market saw an 8% increase in demand for injectable cephalosporins due to rising hospital-acquired infections. Key players include North China Pharmaceutical Group (China) and Aurobindo Pharma (India), collectively holding a 35% market share in the region. The industry faces challenges from antibiotic resistance concerns, leading to a 15% increase in R&D for novel cephalosporin derivatives. Regulatory pressures have driven a 10% increase in investments for improving manufacturing standards. The market is benefiting from the expansion of healthcare access in developing countries, with a 12% growth in demand from emerging markets within the region.
Report Includes
This report is an essential reference for who looks for detailed information on Asia Pacific Cephalosporin Antibiotics API. The report covers data on Asia Pacific markets including historical and future trends for supply, market size, prices, trading, competition and value chain as well as Asia Pacific major vendors¡¯ information. In addition to the data part, the report also provides overview of Cephalosporin Antibiotics API, including classification, application, manufacturing technology, industry chain analysis and latest market dynamics. Finally, a customization report in order to meet user's requirements is also available.
This report aims to provide a comprehensive presentation of the Asia Pacific Cephalosporin Antibiotics API, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cephalosporin Antibiotics API. This report contains market size and forecasts of Cephalosporin Antibiotics API in Asia Pacific, including the following market information:
We surveyed the Cephalosporin Antibiotics API manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
• China
• India
• Japan
• South Korea
• Australia
• Thailand
• Indonesia
• First Generation Cephalosporins
• Second Generation Cephalosporins
• Third-generation Cephalosporins
• Fourth Generation Cephalosporins
• Injection
• Oral
• CSPC Pharmaceutical Group Limited
• Fujian Fukang Pharmaceutical Co., Ltd.
• NCPC Huamin Pharmaceutical Co., Ltd.
• Orchid Pharma Ltd
• Qilu Pharmaceutical Co., Ltd.
• Shandong Lukang Pharmaceutical Co., Ltd.
• Shanghai Pharmaceuticals Holding Co., Ltd.
• Sichuan Antibiotics Industrial Co., Ltd.
• United Laboratories International Holdings Limited
• Zhejiang Medicine Co., Ltd.
Including or excluding key companies relevant to your analysis.
The report also provides analysis of leading market participants including:
• Key companies Cephalosporin Antibiotics API revenues in Asia Pacific market, 2019-2024 (Estimated), ($ millions)
• Key companies Cephalosporin Antibiotics API revenues share in Asia Pacific market, 2023 (%)
• Key companies Cephalosporin Antibiotics API sales in Asia Pacific market, 2019-2024 (Estimated),
• Key companies Cephalosporin Antibiotics API sales share in Asia Pacific market, 2023 (%)
Key Points of this Report:
• The depth industry chain includes analysis value chain analysis, porter five forces model analysis and cost structure analysis
• The report covers Asia Pacific and country-wise market of Cephalosporin Antibiotics API
• It describes present situation, historical background and future forecast
• Comprehensive data showing Cephalosporin Antibiotics API capacities, production, consumption, trade statistics, and prices in the recent years are provided
• The report indicates a wealth of information on Cephalosporin Antibiotics API manufacturers
• Cephalosporin Antibiotics API forecast for next five years, including market volumes and prices is also provided
• Raw Material Supply and Downstream Consumer Information is also included
• Any other user's requirements which is feasible for us
Reasons to Purchase this Report:
• Analyzing the outlook of the market with the recent trends and SWOT analysis
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and non-economic aspects
• Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
• Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
• Distribution Channel sales Analysis by Value
• Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
• Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
• 1-year analyst support, along with the data support in excel format.
1.1 Product Overview and Scope of Cephalosporin Antibiotics API
1.2.1 Asia Pacific Market Size YoY Growth Rate Analysis by Type: 2023 VS 2030
1.2.2 First Generation Cephalosporins
1.2.3 Second Generation Cephalosporins
1.2.4 Third-generation Cephalosporins
1.2.5 Fourth Generation Cephalosporins
1.3.1 Asia Pacific Market Size YoY Growth Rate Analysis by Application: 2023 VS 2030
1.3.2 Injection
1.3.3 Oral
1.4 Asia Pacific Market Growth Prospects
1.4.1 Asia Pacific Revenue Estimates and Forecasts (2019-2030)
1.4.2 Asia Pacific Production Estimates and Forecasts (2019-2030)
2.1 Industry Trends
2.1.1 SWOT Analysis
2.1.2 PESTEL Analysis
2.1.3 Porter’s Five Forces Analysis
2.2 Potential Market and Growth Potential Analysis
3.1 Asia Pacific Production by Manufacturers (2019-2023)
3.2 Asia Pacific Revenue Market Share by Manufacturers (2019-2023)
3.3 Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Asia Pacific Average Price by Manufacturers (2019-2023)
3.5 Manufacturers Production Sites, Area Served, Product Type
3.6 Market Competitive Situation and Trends
3.6.1 Market Concentration Rate
3.6.2 Asia Pacific 5 and 10 Largest Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4.1 Asia Pacific Production
4.1.1 Asia Pacific Production YoY Growth Rate (2019-2023)
4.1.2 Asia Pacific Production, Revenue, Price and Gross Margin (2019-2024)
5.1 Asia Pacific
5.1.1 Asia Pacific Consumption by Country
5.1.2 Asia Pacific Sales, Consumption, Export, Import (2019-2023)
5.1.1 China
5.2.2 India
5.3.3 Japan
5.4.4 South Korea
5.5.5 Australia
5.6.6 Thailand
5.7.7 Indonesia
6.1 Asia Pacific Production Market Share by Type (2019-2024)
6.2 Asia Pacific Revenue Market Share by Type (2019-2024)
6.3 Asia Pacific Price by Type (2019-2024)
7.1 Asia Pacific Production Market Share by Application (2019-2024)
7.2 Asia Pacific Revenue Market Share by Application (2019-2024)
7.3 Asia Pacific Price by Application (2019-2024)
8.1 CSPC Pharmaceutical Group Limited
8.1.1 CSPC Pharmaceutical Group Limited Corporation Information
8.1.2 CSPC Pharmaceutical Group Limited Product Portfolio
8.1.3 CSPC Pharmaceutical Group Limited Production Capacity, Revenue, Price and Gross Margin (2019-2024)
8.1.4 CSPC Pharmaceutical Group Limited Main Business and Markets Served
8.1.5 CSPC Pharmaceutical Group Limited Recent Developments/Updates
8.2 Fujian Fukang Pharmaceutical Co., Ltd.
8.2.1 Fujian Fukang Pharmaceutical Co., Ltd. Corporation Information
8.2.2 Fujian Fukang Pharmaceutical Co., Ltd. Product Portfolio
8.2.3 Fujian Fukang Pharmaceutical Co., Ltd. Production Capacity, Revenue, Price and Gross Margin (2019-2024)
8.2.4 Fujian Fukang Pharmaceutical Co., Ltd. Main Business and Markets Served
8.2.5 Fujian Fukang Pharmaceutical Co., Ltd. Recent Developments/Updates
8.3 NCPC Huamin Pharmaceutical Co., Ltd.
8.3.1 NCPC Huamin Pharmaceutical Co., Ltd. Corporation Information
8.3.2 NCPC Huamin Pharmaceutical Co., Ltd. Product Portfolio
8.3.3 NCPC Huamin Pharmaceutical Co., Ltd. Production Capacity, Revenue, Price and Gross Margin (2019-2024)
8.3.4 NCPC Huamin Pharmaceutical Co., Ltd. Main Business and Markets Served
8.3.5 NCPC Huamin Pharmaceutical Co., Ltd. Recent Developments/Updates
8.4 Orchid Pharma Ltd
8.4.1 Orchid Pharma Ltd Corporation Information
8.4.2 Orchid Pharma Ltd Product Portfolio
8.4.3 Orchid Pharma Ltd Production Capacity, Revenue, Price and Gross Margin (2019-2024)
8.4.4 Orchid Pharma Ltd Main Business and Markets Served
8.4.5 Orchid Pharma Ltd Recent Developments/Updates
8.5 Qilu Pharmaceutical Co., Ltd.
8.5.1 Qilu Pharmaceutical Co., Ltd. Corporation Information
8.5.2 Qilu Pharmaceutical Co., Ltd. Product Portfolio
8.5.3 Qilu Pharmaceutical Co., Ltd. Production Capacity, Revenue, Price and Gross Margin (2019-2024)
8.5.4 Qilu Pharmaceutical Co., Ltd. Main Business and Markets Served
8.5.5 Qilu Pharmaceutical Co., Ltd. Recent Developments/Updates
8.6 Shandong Lukang Pharmaceutical Co., Ltd.
8.6.1 Shandong Lukang Pharmaceutical Co., Ltd. Corporation Information
8.6.2 Shandong Lukang Pharmaceutical Co., Ltd. Product Portfolio
8.6.3 Shandong Lukang Pharmaceutical Co., Ltd. Production Capacity, Revenue, Price and Gross Margin (2019-2024)
8.6.4 Shandong Lukang Pharmaceutical Co., Ltd. Main Business and Markets Served
8.6.5 Shandong Lukang Pharmaceutical Co., Ltd. Recent Developments/Updates
8.7 Shanghai Pharmaceuticals Holding Co., Ltd.
8.7.1 Shanghai Pharmaceuticals Holding Co., Ltd. Corporation Information
8.7.2 Shanghai Pharmaceuticals Holding Co., Ltd. Production Capacity, Revenue, Price and Gross Margin (2019-2024)
8.7.3 Shanghai Pharmaceuticals Holding Co., Ltd. Main Business and Markets Served
8.7.4 Shanghai Pharmaceuticals Holding Co., Ltd. Recent Developments/Updates
8.8 Sichuan Antibiotics Industrial Co., Ltd.
8.8.1 Sichuan Antibiotics Industrial Co., Ltd. Corporation Information
8.8.2 Sichuan Antibiotics Industrial Co., Ltd. Product Portfolio
8.8.3 Sichuan Antibiotics Industrial Co., Ltd. Production Capacity, Revenue, Price and Gross Margin (2019-2024)
8.8.4 Sichuan Antibiotics Industrial Co., Ltd. Main Business and Markets Served
8.8.5 Sichuan Antibiotics Industrial Co., Ltd. Recent Developments/Updates
8.9 United Laboratories International Holdings Limited
8.9.1 United Laboratories International Holdings Limited Corporation Information
8.9.2 United Laboratories International Holdings Limited Product Portfolio
8.9.3 United Laboratories International Holdings Limited Production Capacity, Revenue, Price and Gross Margin (2019-2024)
8.9.4 United Laboratories International Holdings Limited Main Business and Markets Served
8.9.5 United Laboratories International Holdings Limited Recent Developments/Updates
8.10 Zhejiang Medicine Co., Ltd.
8.10.1 Zhejiang Medicine Co., Ltd. Corporation Information
8.10.2 Zhejiang Medicine Co., Ltd. Product Portfolio
8.10.3 Zhejiang Medicine Co., Ltd. Production Capacity, Revenue, Price and Gross Margin (2019-2024)
8.10.4 Zhejiang Medicine Co., Ltd. Main Business and Markets Served
8.10.5 Zhejiang Medicine Co., Ltd. Recent Developments/Updates
9.1 Key Raw Materials Analysis
9.1.1 Key Raw Materials
9.1.2 Key Suppliers of Raw Materials
9.2 Proportion of Manufacturing Cost Structure
9.3 Manufacturing Process Analysis of Cephalosporin Antibiotics API
9.4 Industrial Chain Analysis
10.1 Marketing Channel
10.2 Distributors List
10.3 Customers
11.1 Industry Trends
11.2 Market Drivers
11.3 Market Challenges
11.4 Market Restraints
12.1 Asia Pacific Production, Revenue Forecast (2024-2030)
13.1 Asia Pacific Forecasted Consumption of by Country
14.1 Asia Pacific Production, Revenue and Price Forecast by Type (2024-2030)
14.1.1 Asia Pacific Forecasted Production of by Type (2024-2030)
14.1.2 Asia Pacific Forecasted Revenue of by Type (2024-2030)
14.1.3 Asia Pacific Forecasted Price of by Type (2024-2030)
14.2 Asia Pacific Production, Revenue and Price Forecast by Application (2024-2030)
14.2.1 Asia Pacific Forecasted Production of by Application (2024-2030)
14.2.2 Asia Pacific Forecasted Revenue of by Application (2024-2030)
14.2.3 Asia Pacific Forecasted Price of by Application (2024-2030)
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Author List
16.4 Disclaimer
17.1 Note
17.2 Examples of Clients
Frequently Asked Questions ?
